In this piece, we will take a look at the five stocks to invest in under $20 according to Sio Capital. For more stocks and background on the investment firm, head on to 10 Stocks to Invest In Under $20 According to Michael Castor’s Sio Capital.
5. IsoPlexis Corporation (NASDAQ:ISO)
Sio Capital’s Stake Value: $4.5 million
Percentage of Sio Capital’s 13F Portfolio: 1.37%
Number of Hedge Fund Holders: 7
Stock Price as of May 10, 2022: $2.3
IsoPlexis Corporation (NASDAQ:ISO) is a life sciences company headquartered in Branford, Connecticut, United States. The firm offers devices and technologies that allow its customers situated all over the world to carry out tasks such as studying protein structure.
Sio Capital owned 495,012 IsoPlexis Corporation (NASDAQ:ISO) shares by the end of the fourth quarter of last year, in a $4.5 million stake that represented 1.37% of its investment portfolio. For the same period, 7 of the 924 hedge funds part of Insider Monkey’s portfolio had also invested in the firm.
IsoPlexis Corporation (NASDAQ:ISO) reported $17.25 million in revenue and -$8.99 in GAAP EPS for its fiscal year 2021, beating analyst revenue estimates. At its earning event, the company outlined that it expects its revenue to grow by at least 55% this year.
4. Pardes Biosciences, Inc. (NASDAQ:PRDS)
Sio Capital’s Stake Value: $5.1 million
Percentage of Sio Capital’s 13F Portfolio: 1.54%
Number of Hedge Fund Holders: 18
Stock Price as of May 10, 2022: $2.16
Pardes Biosciences, Inc. (NASDAQ:PRDS) is an American biotechnology firm based in Carlsbad, California. The company focuses its efforts on developing treatments for life threatening diseases, and it is currently working on a treatment for SARS Coronavirus 2 and other similar diseases.
By the end of its latest fiscal year, Pardes Biosciences, Inc. (NASDAQ:PRDS) posted -$10.13 in GAAP EPS alongside reporting cash and equivalents of $268.7 million for the twelve months ending in December 2021. SVB Leernik set an $18 price target for the firm in March 2022, as it stated that the coronavirus pandemic is rapidly evolving, which creates the need for more therapies.
Dr. Castor’s hedge fund held a $5.1 million stake in Pardes Biosciences, Inc. (NASDAQ:PRDS) as part of its Q4 2021 investment portfolio. This came in the form of 312,438 shares and it represented 1.54% of the firm’s investment portfolio. Insider Monkey profiled 924 hedge fund holdings for 2021’s final quarter to discover that 18 had bought the company’s shares.
3. Renovacor, Inc. (NYSE:RCOR)
Sio Capital’s Stake Value: $5.6 million
Percentage of Sio Capital’s 13F Portfolio: 1.7%
Number of Hedge Fund Holders: 14
Stock Price as of May 10, 2022: $3.06
Renovacor, Inc. (NYSE:RCOR) is a precision therapy provider that targets a host of diseases such as cardiomyopathy and uses a variety of genetic modifications to target others. The firm is headquartered in Greenwich, Connecticut, United States.
Sio Capital’s fourth quarter of 2021 portfolio saw the company hold 735,908 Renovacor, Inc. (NYSE:RCOR) shares that were worth $5.6 million and represented 1.7% of its investment portfolio. During the same time period, 14 of the 924 hedge funds surveyed by Insider Monkey had also invested in the firm.
Renovacor, Inc. (NYSE:RCOR) outlined -$0.03 in GAAP EPS and $78.8 million in cash at the end of its fourth fiscal quarter. The company also announced a new chief financial officer in March 2022 and cited confidence in its gene therapies at the same time.
2. Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH)
Sio Capital’s Stake Value: $7 million
Percentage of Sio Capital’s 13F Portfolio: 2.13%
Number of Hedge Fund Holders: 10
Stock Price as of May 10, 2022: $2.78
Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) is a home care platform provider that operates in the United States. The firm has three segments, which cover private home care, health services such as therapies, and medical solutions such as nutritional services.
For its fiscal Q4, Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) reported $414 million in revenue and -$0.68 in GAAP EPS, in a poor set of results that saw it miss Wall Street analyst estimates for both. Subsequently, RBC Capital lowered the company’s price target to $9 from $16 in March 2022, outlining that the labor crisis and pandemic drove the decision.
Sio Capital held a $7 million stake in Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) by the end of Q4 2021. This came in the form of 958,249 shares. During the same time period, 10 of the 924 hedge funds part of Insider Monkey’s research had owned the company’s shares.
Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH)’s largest investor is Jared Nussbaum’s Nut Tree Capital which owns 5.4 million shares that are worth $40 million.
1. Curis, Inc. (NASDAQ:CRIS)
Sio Capital’s Stake Value: $18.4 million
Percentage of Sio Capital’s 13F Portfolio: 5.54%
Number of Hedge Fund Holders: 20
Stock Price as of May 10, 2022: $0.85
Curis, Inc. (NASDAQ:CRIS) is headquartered in Lexington, Massachusetts. The company aims to target several kinds of cancers such as leukemia, lymphomas, solid tumors, and basal cell carcinoma.
Dr. Castor’s investment firm owned 3.8 million Curis, Inc. (NASDAQ:CRIS) shares for its fourth quarter investment portfolio. These were worth $18.4 million and represented 5.54% of the firm’s overall investments. Insider Monkey diligently scanned 924 hedge fund holdings for Q4 2021 and discovered that 20 had also invested in the cancer treatment provider.
Curis, Inc. (NASDAQ:CRIS) raked in $2 million in revenue alongside reporting -$0.18 in GAAP EPS for its first fiscal quarter, missing analyst estimates for both. H.C. Wainwright stuck with a $20 price target for the company in April 2022, highlighting that good things might come from clinical trials of the company’s drugs.
Lee Ainslie’s Maverick Capital is Curis, Inc. (NASDAQ:CRIS)’s largest investor via a $37 million stake that comes through owning 7.7 million shares.
You can also take a peek at the 10 Stocks to Buy Now According to Wayne Yu’s BCK Capital and Gillson Capital Stock Portfolio: 10 Best Dividend Stocks.
